Abstracts Archive - Page 2066 of 2425 - ACR Meeting Abstracts

Abstract Number: 2780 • 2013 ACR/ARHP Annual Meeting
Cumulative Exposure To Elevated Inflammatory Markers Is Associated With Increased Burden Of Atherosclerosis In Psoriatic Arthritis Patients: A Cohort Study
Lihi Eder¹, Arane Thavaneswaran², Vinod Chandran³, Richard J. Cook⁴ and Dafna D. Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Cardiovascular morbidity is increased in patients with psoriatic arthritis (PsA). Traditional cardiovascular risk factors do not fully explain this excessive risk. It is unclear…
Abstract Number: 2781 • 2013 ACR/ARHP Annual Meeting
The Disease Characteristics and Predictors Of Minimal Disease Activity On TNF Blockers- Results From A Longitudainal Observational Cohort
Amir Haddad¹, Arane Thavaneswaran¹, Ioana Ruiz Arruza², Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: A state of Minimal Disease Activity (MDA) has been defined and validated as a target for treatment in PsA. The purpose of the study…
Abstract Number: 2782 • 2013 ACR/ARHP Annual Meeting
Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial
Eli Miloslavsky¹, Ulrich Specks², Peter A Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke Unversity Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Retrospective studies have demonstrated that repeat rituximab treatment may be effective in re-inducing remission in relapsing ANCA-associated vasculitis. We analyzed data from the Rituximab…
Abstract Number: 2783 • 2013 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine For Maintenance In Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis: Follow Up At 39 Months
Benjamin Terrier¹, Christian Pagnoux², Alexandre Karras³, Chahera Khouatra⁴, Olivier Aumaître⁵, Pascal Cohen⁶, Francois Maurier⁷, Olivier Decaux⁸, Hélène Desmurs-Clavel⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puéchal¹⁴, Luc Mouthon¹⁵ and Loic Guillevin¹⁶, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴CHU Lyon, Lyon, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹²Internal Medicine, Hôpital de Niort, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France
Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis: Follow up at 39 months.Background/Purpose: Rituximab was shown to be as effective as cyclophosphamide to…
Abstract Number: 2784 • 2013 ACR/ARHP Annual Meeting
Mononeuritis Multiplex Predicts The Need For Immunosuppressive Or Immunomodulatory Drugs For Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa and Microscopic Polyangiitis Patients Without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon², Loic Guillevin⁸ and French Vasculitis Study Group (FVSG)², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Immunology and Allergology, Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland, Geneva, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA), polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) without poor-prognosis factors, as defined by their 1996 Five-Factor Scores…
Abstract Number: 2785 • 2013 ACR/ARHP Annual Meeting
Urinary Inflammatory Cells Strongly Reflect the Disease Activity and Renal Function in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Yoko Wada¹, Minoru Sakatsume², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ³School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: The antineutrophil cytoplasmic autoantibody (ANCA)- associated vasculitides (AAVs) include microscopic polyangiitis (MPA), granulomatosis with polyangitis (GPA; formerly Wegener’s), and eosinophilic granulomatosis with polyangitis (EGPA).…
Abstract Number: 2786 • 2013 ACR/ARHP Annual Meeting
Review Of The Expert Panel Methodology In The Diagnostic and Classification Criteria For Vasculitis Study: A Pilot Study
Cristina Ponte¹, Anthea Craven², Joanna Robson², Peter C. Grayson³, Ravi Suppiah⁴, Richard A. Watts⁵, Peter A. Merkel⁶ and Raashid A. Luqmani², ¹Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHLN and Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ²Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Section of Rheumatology & the Clinical Epidemiology Unit, Boston University School of Medicine, Vasculitis Center, Boston, MA, ⁴Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁵Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, ⁶Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Diagnostic and Classification Criteria for Vasculitis (DCVAS) Study is a multinational observational study to develop diagnostic criteria and to update classification criteria for…
Abstract Number: 2787 • 2013 ACR/ARHP Annual Meeting
The Effect Of Smoking On The Clinical Expression Of ANCA-Associated Vasculitis
Neil Basu¹, Aladdin Mohammad², Richard A. Watts³, Paul Gatenby⁴, Luis F. Flores-Suarez⁵ and Alfred Mahr⁶, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Department of Rheumatology, Skåne University Hospital, Lund, Sweden, ³Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, ⁴ANU Medical School, The Canberra Hospital, Canberra, Australia, ⁵Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ⁶Department of Internal Medicine, Hospital Saint-Louis, Paris, France
Background/Purpose: It is well recognized that smoking has immuno-modulatory effects in several chronic inflammatory disorders. For ANCA-associated vasculitis (AAV), which includes granulomatosis with polyangiitis (GPA)…
Abstract Number: 2788 • 2013 ACR/ARHP Annual Meeting
Reliability and Responsivenss Of The Standardized Universal Pain Evaluations For Rheumatology Providers For Children and Youth (SUPER-KIDZ)
Nadia Luca¹, Jennifer N. Stinson², Susanne M. Benseler³, Brian M. Feldman⁴, Dorcas Beaton^5,6 and Ahmed Bayoumi⁷, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Anesthesia and Pain Medicine, Hospital for Sick Children, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁵Research, Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, Canada, ⁶Scientist, Institute for Work & Health, Toronto, ON, Canada, ⁷General Internal Medicine, Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Pain is the most common symptom in children and youth with juvenile idiopathic arthritis (JIA), however, currently there is no comprehensive validated pain measure…
Abstract Number: 2789 • 2013 ACR/ARHP Annual Meeting
Enhancing Uveitis Screening Compliance In Juvenile Idiopathic Arthritis Patients
Melissa S Oliver¹, Jennifer E. Weiss², Suzanne C. Li³, Kathleen A. Haines², Ginger L. Janow², Esi Morgan DeWitt⁴ and Yukiko Kimura², ¹Pediatrics, UMDNJ New Jersey Medical School, Newark, NJ, ²Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁴Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Chronic uveitis is one of the more severe morbidities associated with juvenile idiopathic arthritis (JIA). Risk of developing uveitis, and the frequency of uveitis…
Abstract Number: 2790 • 2013 ACR/ARHP Annual Meeting
The Research In Arthritis In Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Are We Achieving Clinically Important Outcomes?
Deborah M. Levy¹, Shirley ML Tse¹, Elizabeth Stringer², Jaime Guzman³, Roberta A. Berard⁴, Karen Watanabe Duffy⁵, Dax Rumsey¹, Mercedes O. Chan³, Rosie Scuccimarri⁶, Adam M. Huber⁷, Lori B. Tucker³, Rae SM Yeung¹, Ciaran M. Duffy⁵, Kiem Oen⁸ and The ReACCh Out Investigators⁹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ³Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Pediatrics, Children's Hospital of Winnipeg and University of Manitoba, Winnipeg, MB, Canada, ⁹The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Recent data suggests that achievement of inactive disease and early disease remission may result in improved outcomes for patients with juvenile idiopathic arthritis (JIA). …
Abstract Number: 2791 • 2013 ACR/ARHP Annual Meeting
Telephone Consultation Usage In a Pediatric Rheumatology Clinic: Considerations In Optimizing Nursing Resources
Julie Lemieux¹, Audrey Tran², Vincent Brienza³ and Roman Jurencak³, ¹Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Telephone consultation is essential to the delivery of patient care in the ambulatory care clinics at the Children’s Hospital of Eastern Ontario (CHEO). Our…
Abstract Number: 2792 • 2013 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures
Julia G. Harris^1,2, Esi Morgan DeWitt³, Ronald M. Laxer^4,5, Stacy P. Ardoin⁶, Beth S. Gottlieb⁷, Judyann C. Olson^1,2, Murray H. Passo⁸, Jennifer E. Weiss⁹, Daniel J. Lovell¹⁰, Tzielan C. Lee¹¹, Sheetal S. Vora^12,13, Nancy Griffin¹⁴, Jason A. Stock¹⁵, Lynn M. Darbie¹⁴ and Catherine A. Bingham¹⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁷Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁸Pediatrics, Medical University of South Carolina, Charleston, SC, ⁹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²University of North Carolina Chapel Hill, Chapel Hill, NC, ¹³Levine Children's Hospital and Carolinas Medical Center, Charlotte, NC, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning network designed to improve outcomes of juvenile idiopathic arthritis (JIA) care. Teams…
Abstract Number: 2793 • 2013 ACR/ARHP Annual Meeting
Towards Developing a Rheumatology-Specific Transition Of Care Program
Rina Mina¹, Janalee Taylor², Pamela A. Heydt³, Terry M. Moore⁴, Julie V. Ranz⁵, Mary Beth Burns⁶, Paula G. Melson⁷, Abigail Nye⁶, Jill Segerman⁵, Yolanda Farhey⁸, John Houk⁹, Avis Ware⁹, Jennifer L. Huggins⁵ and Lisa Vaughn⁶, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²William S. Rowe Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Childrens Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Cincinnati Chiildren's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Rheumatology, Children's Hosp Medical Center, Cincinnati, OH, ⁸University of Cincinnati, Cincinnati, OH, ⁹Immunology, Allergy and Rheumatology, University of Cincinnati, Cincinnati, OH
Background/Purpose: Background: Because of their considerable medical challenges, adolescents and young adults with pediatric-onset rheumatic diseases are often reliant on the health care system, and…
Abstract Number: 2794 • 2013 ACR/ARHP Annual Meeting
Characterisation Of Antigens Driving In Situ Autoantibody Production In Human Lupus Tubulointerstitial Nephritis (TIN)
Andrew Kinloch¹, Scott Henderson¹, Natalya Kaverina², Anthony Chang³, D. James Haddon⁴, Justin Jarrel⁴, Carole Henry Dunand², Patrick C. Wilson⁵, Paul Utz⁴ and Marcus R. Clark⁶, ¹Rheumatology and Knapp Center of Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology and Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ³Pathology, University of Chicago, Chicago, IL, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Rheumatology and Knapp center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁶Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL
Background/Purpose: We have demonstrated that the degree of tubulointerstitial nephritis (TIN) on diagnostic biopsy predicts progression to renal failure. TIN is associated with tertiary lymphoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].